CG brings back the crossover round, reeling in $105M to fund phase 3 bladder cancer trial

[cafead]

via CG Oncology has raised the rarely seen crossover round. Once ubiquitous, the pre-IPO rounds have dried up in the biotech bear market—but CG’s fully enrolled phase 3 bladder cancer clinical trial has persuaded investors to dig out their checkbooks and pump $105 million into the business.

article source